Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring Prostate cancer, LHRH, hormone therapy, testosterone level
Eligibility Criteria
Inclusion Criteria: All patients who elect to undergo brachytherapy for the treatment of adenocarcinoma of the prostate and who are otherwise recommended treatment with LHRH agonist. All patients must have a confirmed histological diagnosis of adenocarcinoma of the prostate and elect to be treated with transperineal implantation of the prostate. Eligible patients will have confirmed clinical stage T1 or T2 (UICC 1997 staging system) with PSA > 10 but < 15 and Gleason score < 7, OR PSA < 10 and Gleason score = 7 OR Prostate volume > 50cc as measured on trans rectal ultrasound While criteria 1 and 2 are mutually exclusive, criteria 3 can be present alone or in combination with criteria 1 OR 2. Otherwise patients should be able to give informed consent and have a life expectancy. 2 years. Exclusion Criteria: -
Sites / Locations
- BC Cancer Agency - Vancouver Island CentreRecruiting
Arms of the Study
Arm 1
Experimental
Leuprolide preparations
One versus three-month Leuprolide preparations in patients otherwise suitable for our Brachytherapy Program